326 related articles for article (PubMed ID: 35609768)
1. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
2. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb A; Herranz N; Arce-Gallego S; Miranda S; Buroni L; Yuan W; Athie A; Casals T; Carmichael J; Rodrigues DN; Gurel B; Rescigno P; Rekowski J; Welti J; Riisnaes R; Gil V; Ning J; Wagner V; Casanova-Salas I; Cordoba S; Castro N; Fenor de la Maza MD; Seed G; Chandran K; Ferreira A; Figueiredo I; Bertan C; Bianchini D; Aversa C; Paschalis A; Gonzalez M; Morales-Barrera R; Suarez C; Carles J; Swain A; Sharp A; Gil J; Serra V; Lord C; Carreira S; Mateo J; de Bono JS
Eur Urol; 2021 Feb; 79(2):200-211. PubMed ID: 33176972
[TBL] [Abstract][Full Text] [Related]
3. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
4. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA Damage Response in Prostate and Breast Cancer.
Wengner AM; Scholz A; Haendler B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
[TBL] [Abstract][Full Text] [Related]
6.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
7. Modulation of hypersensitivity to oxidative DNA damage in ATM defective cells induced by potassium bromate by inhibition of the Poly (ADP-ribose) polymerase (PARP).
Mosesso P; Piane M; Pepe G; Cinelli S; Chessa L
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt A):117-123. PubMed ID: 30389154
[TBL] [Abstract][Full Text] [Related]
8. Synergistic action of combined PARP and ATR inhibition in prostate cancer with ATM loss.
Tregunna R
Nat Rev Urol; 2021 Jan; 18(1):4. PubMed ID: 33262506
[No Abstract] [Full Text] [Related]
9. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
Zhou Y; Börcsök J; Adib E; Kamran SC; Neil AJ; Stawiski K; Freeman D; Stormoen DR; Sztupinszki Z; Samant A; Nassar A; Bekele RT; Hanlon T; Valentine H; Epstein I; Sharma B; Felt K; Abbosh P; Wu CL; Efstathiou JA; Miyamoto DT; Anderson W; Szallasi Z; Mouw KW
Sci Adv; 2023 Nov; 9(47):eadg2263. PubMed ID: 37992168
[TBL] [Abstract][Full Text] [Related]
10. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase for the Efficient Treatment of Cancer.
Shao J; Huang L; Lai W; Zou Y; Zhu Q
Molecules; 2023 Jun; 28(11):. PubMed ID: 37298997
[TBL] [Abstract][Full Text] [Related]
12. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells.
Martín-Guerrero SM; Casado P; Muñoz-Gámez JA; Carrasco MC; Navascués J; Cuadros MA; López-Giménez JF; Cutillas PR; Martín-Oliva D
Exp Eye Res; 2019 Nov; 188():107790. PubMed ID: 31494107
[TBL] [Abstract][Full Text] [Related]
14. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
Moolmuang B; Ruchirawat M
J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808
[TBL] [Abstract][Full Text] [Related]
15. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z
J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
[TBL] [Abstract][Full Text] [Related]
16. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance.
Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
[TBL] [Abstract][Full Text] [Related]
17. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR).
Wang LW; Jiang S; Yuan YH; Duan J; Mao ND; Hui Z; Bai R; Xie T; Ye XY
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458687
[TBL] [Abstract][Full Text] [Related]
19. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
